Trial reportInternational journal of clinical pharmacy2011
Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain.
Trial report in International journal of clinical pharmacy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors influencing national implementation of innovations within community pharmacy: a systematic review applying the Consolidated Framework for Implementation Research.Implementation science : IS · 2019Pooled it
- Knowledge and Use of Over-the-counter Drugs in Italy: An Exploratory Survey-based Study in the General Population.Current neuropharmacology · 2023Article
- A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults.Journal of pharmaceutical policy and practice · 2021Review
- Nutrition Education and Community Pharmacy: A First Exploration of Current Attitudes and Practices in Northern Ireland.Pharmacy (Basel, Switzerland) · 2019Article
- A scoping review of weight bias by community pharmacists towards people with obesity and mental illness.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2016Article
- Promoting weight management services in community pharmacy: perspectives of the pharmacy team in Scotland.International journal of clinical pharmacy · 2015Article
- Views of the Scottish general public on community pharmacy weight management services: international implications.International journal of clinical pharmacy · 2012Article
- Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study.BMJ open · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives of the studyTo describe community pharmacists' early experiences, views and attitudes with over-the-counter orlistat, 9 months post legal re-classification from November 2009 to January 2010.
setting13,200 (81%) randomly selected registered community pharmacies across Great Britain out of a potential 16,200.
methodsA cross-sectional postal questionnaire survey of the main pharmacist with greatest responsibility for over-the-counter (OTC) supply.
main outcome measuresPharmacists' early experiences, views and attitudes of orlistat supply, demographic data of respondents and personal opinions with the supply of orlistat.
resultsQuestionnaires were returned by 32.4% (n = 4,026) of pharmacists surveyed. Just over half (51.9%, n = 2,091) reported no sales of orlistat in the previous 4 weeks with only 5.1% (n = 203) reporting frequent (5.1%) or very frequent supply in the same time frame. Two thirds (66.5%, n = 2,676) agreed or strongly agreed that the sale of orlistat was a good opportunity to extend their role as a healthcare professional and 92% (n = 3,712) felt confident in their ability to supply this product. Over half (57.9%, n = 2,334) admitted that customers frequently complained about the cost of the product and 47.8% (n = 1,926) agreed that customers could misuse the product.
conclusionDespite community pharmacists welcoming orlistat re-classification to increase medicines availability as an opportunity to extend their healthcare professional role there were concerns about poor public uptake, high cost and the potential for misuse. Exploratory studies collecting the views and experiences of the general public about the access and provision of weight management services through community pharmacies are warranted.
Indexed as
Identifiers
21573977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.